Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (25,170,372)	$ (5,310,814)
Adjustments to reconcile net loss to Net cash used in operating activities:
Stock based compensation	7,407,331	318,484
Amortization of operating lease right-of-use asset	60,639
Depreciation	71,383
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,107,236	(54,960)
Other Assets	(41,994)
Accounts payable	1,196,900	(152,239)
Accrued expenses	(1,236,328)	1,277,222
Right-of-use liability	(35,883)
Net cash used in operating activities	(16,641,088)	(3,922,307)
Cash flows from investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.	3,718,742
Purchase of property and equipment	(373,340)	(429,138)
Net cash provided by/(used in) investing activities	3,345,402	(429,138)
Cash flows from financing activities:
Proceeds from - ArTara Private Placement, net of offering costs	1,867,580
Proceeds from - Proteon Private Placement, net of offering costs	12,413,337
Proceeds from - Series 1 Convertible Preferred Stock, net of offering costs	25,318,706
Proceeds from September Series 1 Convertible Preferred, net of offering costs	66,283,552
Proceeds from September Common Stock, net of offering costs	73,570,660
Repayments under short-term debt	(1,297,777)
Proceeds from the exercise of stock options	530,301
Proceeds from private placements		499,999
Net cash provided by financing activities	178,686,359	499,999
Net increase/(decrease) in cash and cash equivalents and restricted cash	165,390,673	(3,851,446)
Cash and cash equivalents and restricted cash - beginning of year	564,124	5,549,952
Cash and cash equivalents and restricted cash - end of year	165,954,797	1,698,506
Cash and cash equivalents	165,904,797	1,698,506
Restricted cash	50,000
Cash and cash equivalents and restricted cash	165,954,797	1,698,506
Cash paid for:
Interest	26,353
Income Taxes
Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses	121,712
Purchase of insurance agreement with notes payable	1,668,570
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.	34,532,627
Settlement of RSUs	$ 21